# Delving into the Metabolism of Sézary Cells: A Brief Review

## TL;DR

This review explores how targeting the metabolism of Sézary cells could lead to new treatments for Sézary syndrome, an aggressive skin cancer.

## Contribution

The paper highlights the potential of targeting energy metabolism in Sézary cells as a novel therapeutic strategy.

## Key findings

- Metabolic reprogramming contributes to tumor progression in Sézary syndrome.
- Genetic alterations disrupt metabolic pathways, potentially driving cancer development.
- Targeting cancer metabolism is a promising strategy for developing new therapies for Sézary syndrome.

## Abstract

Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoproliferative disorders caused by the accumulation of neoplastic T or B lymphocytes in the skin. Sézary syndrome (SS) is an aggressive and rare form of cutaneous T cell lymphoma (CTCL) characterized by an erythroderma and the presence of atypical cerebriform T cells named Sézary cells in skin and blood. Most of the available treatments for SS are not curative, which means there is an urgent need for the development of novel efficient therapies. Recently, targeting cancer metabolism has emerged as a promising strategy for cancer therapy. This is due to the accumulating evidence that metabolic reprogramming highly contributes to tumor progression. Genes play a pivotal role in regulating metabolic processes, and alterations in these genes can disrupt the delicate balance of metabolic pathways, potentially contributing to cancer development. In this review, we discuss the importance of targeting energy metabolism in tumors and the currently available data on the metabolism of Sézary cells, paving the way for potential new therapeutic approaches aiming to improve clinical outcomes for patients suffering from SS.